Onkológia 1/2011

A patient with metastatic colorectal adenocarcinoma treated with chemotherapy in combination with bevacizumab

Colorectal carcinoma (CRC) is the third most common type of cancer and the second most leading cause of death. The combination of cytostatics (irinotecan, oxaliplatin, and fluorouracil) and monoclonal antibodies (bevacizumab, cetuximab or panitumumab) represents the standard first-line treatment of metastatic CRC (mCRC). The objective of this case report is to mediate an experience with a mCRC patient treated with bevacizumab, oxaliplatin, and fluorouracil (5-FU) with a partial response after three and six months. Neurotoxicity and neutropenia were noticed side effects. Oxaliplatin was excluded due to neurotoxicity and 5-FU dose reduced due to neutropenia Venous thrombosis in the right axillary vein developed during bevacizumab therapy. The patient is being continued with bevacizumab and 5-FU after nine-month treatment when the disease is stable.

Keywords: colorectal carcinoma, bevacizumab, venous thrombosis, oxaliplatin, neurotoxicity.